Considering the established link between EMT, tumor metastasis, and poor prognosis in EGFR-mutant NSCLC, we investigated the effects of PLK1 inhibitors combined with osimertinib on the migratory properties of resistant cells. This evidence concerns the gene PLK1 and neoplasm.